Literature DB >> 18926057

Influence of cetirizine and levocetirizine on two cytokines secretion in human airway epithelial cells.

Mei-Yin Shih1, Jeng-Yuan Hsu, Yueh-Shan Weng, Lin-Shien Fu.   

Abstract

Recent studies suggest that several second-generation antihistamines can modulate various inflammatory reactions besides their H(1)-receptor antagonism. The antihistamine cetirizine is a racemic mixture of levocetirizine and dextrocetirizine. The aim of this study was to investigate the effects of these two antihistamines (cetirizine and levocetirizine) on granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin (IL)-8 secretion in A549 human airway epithelial cells. A549 cells were preincubated with cetirizine (0.1, 1, 2.5, 5, and 10 microM) or levocetirizine (0.1, 1, 2.5, 5, and 10 microM) individually for 16 hours and were then stimulated with IL-1beta for 8 hours. The levels of GM-CSF and IL-8 in cultured supernatants were measured by enzyme-linked immunosorbent assay (ELISA). Our data showed that cetirizine (5 and 10 microM) and levocetirizine (2.5, 5, and 10 microM) significantly suppressed GM-CSF secretion from A549 cells stimulated with IL-1beta (p<0.05). Cetirizine (10 microM) and levocetirizine (5 and 10 microM) significantly suppressed IL-8 secretion after A549 was stimulated. The suppressive effect was comparable between levocetirizine, 2.5 microM, and cetirizine, 5 microM, as well as levocetirizine, 5 microM, and cetirizine, 10 microM. Moreover, levocetirizine, 5 microM, was better than cetirizine, 5 microM, on suppressing IL-8 secretion, but such a difference did not appear in other conditions. Our results suggest that cetirizine and levocetirizine at higher concentrations can reduce the release of GM-CSF and IL-8 from A549 cells stimulated with IL-1beta. These observations indicate that the two second-generation antihistamines may exert anti-inflammatory effects beyond histamine H(1)-receptor antagonist, and levocetirizine plays a major role in terms of this activity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18926057     DOI: 10.2500/aap.2008.29.3156

Source DB:  PubMed          Journal:  Allergy Asthma Proc        ISSN: 1088-5412            Impact factor:   2.587


  2 in total

1.  Phase II trial of levocetirizine with capecitabine and bevacizumab to overcome the resistance of antiangiogenic therapies in refractory metastatic colorectal cancer.

Authors:  Manik Amin; Monica Desai; Kathryn Trinkaus; Amberly Brown; Andrea Wang-Gillam; Benjamin Tan; Joel Picus; Steven Sorscher; Maureen Highkin; Kim Lears; Albert C Lockhart
Journal:  J Gastrointest Oncol       Date:  2019-06

2.  The anti-inflammatory effects of levocetirizine--are they clinically relevant or just an interesting additional effect?

Authors:  Garry M Walsh
Journal:  Allergy Asthma Clin Immunol       Date:  2009-12-17       Impact factor: 3.406

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.